Sentences with phrase «of novel therapeutic approaches»

Carcinomas arise from epithelial cells, and tumor progression involves a loss of polarity, so an understanding of cell polarity is important in the identification of novel therapeutic approaches to cancer.

The George lab is currently performing preclinical studies for the future development of novel therapeutic approaches including Deep Brain Stimulation, Optogenetics, Chemogenetics and Precision medicine.

«Targeting such pathways, as for instance the Wnt pathway presented in this study, may result in the creation of novel therapeutic approaches for frontotemporal dementia.»

Not exact matches

Hear the story behind Backstage Capital Headliner Novoron Bioscience, a San Diego - based biotech company developing novel therapeutic approaches to address disorders of the central nervous system.

«At the same time, as the human ZNF217 is associated with poor survival in a variety of cancers, understanding how this protein operates in physiological conditions may help to predict cancer risk, achieve earlier diagnosis and provide novel therapeutic approaches.»

We rely on high quality basic and translational respiratory science, such as these latest findings, to develop novel therapeutic approaches for the millions of patients suffering from devastating and often fatal respiratory conditions.

Therefore, a novel therapeutic approach in inflammatory breast cancer could involve a combination of conventional chemotherapy with small - molecule inhibitors of the Cdk2 cell cycle kinase.

Dr. Paul R. Sanberg, Distinguished University Professor, a co-author of the paper, concluded that «these novel data showing BSCB damage in subacute and chronic ischemic stroke may lead to development of new therapeutic approaches for patients with ischemic cerebral infarction.»

«Thus, administration of soluble Del - 1 may provide the platform for developing novel therapeutic approaches for neuroinflammatory and demyelinating diseases, especially multiple sclerosis.»

To achieve gene editing in mice with thalassemia, professor of therapeutic radiology and of genetics Peter M. Glazer, M.D. and his co-authors developed an alternative approach using a novel combination of nanoparticles, synthetic pieces of DNA, and a simple IV injection.

His primary clinical and research focus is dementia, with specific areas of interest including biomarkers to assist in the diagnosis and understanding of disease mechanisms for Alzheimer's and Parkinson's disease, and translational research using novel therapeutic approaches.

These findings suggest a novel therapeutic approach to protect the kidney from scarring and provide a compelling rationale to test the use of Wnt secretion inhibitors for the treatment of kidney fibrosis and other progressive scarring disorders.

Targeting this «wound response» of cancer stem cells can potentially provide a novel approach for therapeutic invention, said researchers from the National Cancer Institute - designated Dan L. Duncan Cancer Center at Baylor College of Medicine.

«These studies identify telomeres as a new molecular route implicated in the origin of liver diseases such as cirrhosis, hepatitis or liver cancer, as well as novel therapeutic approaches to prevent and combat them,» concluded the researchers.

Dr. Qimin Zhan, Principal Investigator of this project and the Director of State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences Cancer Hospital, said, «For sure, the findings of this project provide novel insights into understanding of underlying mechanism for this malignant ESCC, and enable us to explore potential diagnostic biomarkers and drug targets, and to develop useful clinical therapeutic approaches.

However, coreceptor - specific ZFNs represent a novel therapeutic approach to recapitulate this success via autologous transplantation of gene - modified hematopoietic stem cells and mature CD4 + T cells.

The designation recognizes the Center's collaborative environment and expertise in harnessing translational research to bridge scientific discovery to clinical delivery, with the ultimate goal of successfully introducing novel diagnostic, therapeutic and preventive approaches to cancer.

We aim to identify molecular, circuit, and network mechanisms of cognitive dysfunction and to develop novel therapeutic approaches to restore brain functions in AD and related disorders.

The second focus on my research is the development of novel therapeutic vaccine approaches for cancer.

Selectivity of the therapeutic approach is achieved by producing an enzyme called E. coli purine nucleoside phosphorylase (PNP) directly within tumor cells and using the enzyme to generate novel chemotherapy in the tumor mass itself.

Biomedcode offers customized services that include the detailed and in - depth scientific consulting at all stages of designing the best approach for the evaluation of a novel therapeutic.

The resulting data are being combined in a systems biology approach with high - resolution clinical phenotyping and findings obtained with a large array of established and novel in vitro, ex vivo and in vivo disease models to identify disease - associated genetic variants, disease - defining molecular signatures, and potential targets for therapeutic intervention.

Our group is specifically working on improvement of islet isolation and transplantation protocols in clinical practice and the development of novel therapeutic options in the field of beta cell replacement with a clear translational «bench to bedside» approach by linking experimental research with preclinical and clinical work:

The journal aims to promote novel concepts, programs, technologies, protocols, therapeutic agents, and alternative approaches for the early detection, intervention and treatment of human malignancies and closely associated diseases.

In addition, we employ high throughput screening (HTS), cheminformatics, and medicinal chemistry of novel small molecule reagents that aid in validating novel therapeutic approaches and in understanding the biology of signaling in the central nervous system.

Dr. Mayer is a key component of the Vanderbilt - Ingram Cancer Center (VICC) Breast Cancer Program, where her role is to implement and conduct investigator - initiated, mechanism - based clinical and translational trials in breast cancer, focusing in novel diagnostic and therapeutic approaches.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

The goal of her laboratory is to combine high - resolution computational reconstructions of the microbiome with synthetic biology to devise innovative approaches to create novel therapeutic interventions and investigate the underlying ecology of skin microbial communities.

It has invested more than $ 450 million in research to date, almost 90 percent for translational research; funded testing of more than 100 therapeutic targets for Parkinson's disease (PD); and has undertaken novel industry partnerships to support early - stage promising therapeutic approaches.

The Zhang laboratory studies ovarian cancer biology with the goal of developing novel therapeutic approaches to combat the disease with precision.

Together with our collaborators in other UT Health San Antonio departments, we are currently investigating if prohibiting the accumulation of DNA abnormalities can be used as a novel therapeutic approach for treating MDS.

«Our study also highlights that growth of normal cells and cancer cells is driven by different gene switches, suggesting that further work to find ways to control the activity of such disease - specific switches could lead to novel, highly specific approaches for therapeutic intervention», says Professor Jussi Taipale, who led the study.

We report that targeting miR - 181a regulates axonal growth, and that miR - 181a inhibition may be a novel therapeutic approach for axonal regeneration of neurons affected by PD.

This study will greatly expand our knowledge of the biological processes within plaques that lead to disease and provide novel therapeutic approaches that aim to achieve long - term oral health by specifically removing cariogenic species and leaving beneficial or harmless populations intact.

These tumor suppressor genes are two of the most frequently altered genes in human cancer, and understanding how they function at the molecular level will both refine our fundamental understanding of this disease and suggest novel therapeutic approaches to treat it.

Our aim is the development of novel, disease - modifying therapeutic approaches for protein misfolding neurodegenerative diseases.

Ideally, identification of mediators of the inflammatory response in AMD will yield novel therapeutic approaches to this common and often severe form of blindness, in the form of either blocking or inducing TLR2 signaling events.

Modeling mRNA expression heterogeneity in tumors through bimodal profiles is a novel powerful approach with the potential to uncover therapeutic targets that benefit subsets of cancer patients.

Clinical and Regenerative medicine refers to development and implementation of advanced therapeutic approaches that may involve the support of expertise in gene / cell therapy, tissue engineering, pharmacology and pharmacogenomics, development of novel molecular target therapy.

An enhanced understanding of the skin microbiome is necessary to gain insight into microbial involvement in human skin disorders and to enable novel promicrobial and antimicrobial therapeutic approaches for their treatment.

Research Interests Critical care of polytrauma patients, troponin as a biomarker in traumatic myocarditis, the application of Continuous Renal Replacement Therapy (dialysis) for companion animals with acute kidney failure, advanced therapeutic approaches to immune mediated hemolytic anemia, and novel laboratory assessment of coagulopathies (including thromboelastography and platelet aggregometry).